4basebio PLC (AIM: 4BB) announced the appointment of Richard Bungay as Chief Financial Officer, effective July 2026. Bungay will replace David Roth, who stepped down from the board earlier this year.

Bungay brings over 30 years of senior finance experience in the pharmaceutical and biotechnology sectors. He previously served as CEO and CFO at Diurnal Group plc, which was acquired by Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in 2022. He also held CEO and CFO positions at Mereo Biopharma Group plc (NASDAQ: MREO) and CFO at Verona Pharma.

Most recently, Bungay worked at Sitala Bio Limited, where he helped lead a strategic repositioning and Series A funding round, and executed an in-licensing deal with Fosun Pharma valued at up to $670 million.

The company also announced board changes effective May 31, 2026. Alexander Link and Alan Malus will step down as Non-executive Directors due to other professional commitments. Dr. Heikki Lanckriet will replace Link as 2invest AG's board appointee, while Cornel Chiriac is intended to replace Malus, subject to due diligence and regulatory approval.

"Richard has had a long and accomplished career in the industry, bringing significant experience with high growth public and private companies," said Dr. Amy Walker, CEO of 4basebio. "4basebio is transitioning into a phase of accelerated commercial growth, and his strategic and financial expertise will be invaluable to support us on this journey."

4basebio specializes in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics. The Cambridge-based company uses proprietary enzymatic DNA synthesis technology to produce GMP-grade synthetic DNA and mRNA.